Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal therapy, consisting mostly of a combination of surgery, radiother...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Pearson, Joshua R. D., Cuzzubbo, Stefania, McArthur, Simon, Durrant, Lindy G., Adhikaree, Jason, Tinsley, Chris J., Pockley, A. Graham, McArdle, Stephanie E. B.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594513/
https://ncbi.nlm.nih.gov/pubmed/33178210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.582106
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars